Inhibition of Gαs/cAMP Signaling Decreases TCR-Stimulated IL-2 Transcription in CD4(+) T Helper Cells

Overview

Journal J Mol Signal

Publisher Ubiquity Press

Date 2016 Apr 21

PMID 27096000

Citations 4

Authors

Thomas R Hynes

Evan A Yost

Stacy M Yost

Cassandra M Hartle

Braden J Ott

Catherine H Berlot

Affiliations

Soon will be listed here.

Abstract

Background: The role of cAMP in regulating T cell activation and function has been controversial. cAMP is generally known as an immunosuppressant, but it is also required for generating optimal immune responses. As the effect of cAMP is likely to depend on its cellular context, the current study investigated whether the mechanism of activation of Gαs and adenylyl cyclase influences their effect on T cell receptor (TCR)-stimulated interleukin-2 (IL-2) mRNA levels.

Methods: The effect of blocking Gs-coupled receptor (GsPCR)-mediated Gs activation on TCR-stimulated IL-2 mRNA levels in CD4(+) T cells was compared with that of knocking down Gαs expression or inhibiting adenylyl cyclase activity. The effect of knocking down Gαs expression on TCR-stimulated cAMP accumulation was compared with that of blocking GsPCR signaling.

Results: ZM-241385, an antagonist to the Gs-coupled A2A adenosine receptor (A2AR), enhanced TCR-stimulated IL-2 mRNA levels in primary human CD4(+) T helper cells and in Jurkat T cells. A dominant negative Gαs construct, GαsDN3, also enhanced TCR-stimulated IL-2 mRNA levels. Similar to GsPCR antagonists, GαsDN3 blocked GsPCR-dependent activation of both Gαs and Gβγ. In contrast, Gαs siRNA and 2',5'-dideoxyadenosine (ddA), an adenylyl cyclase inhibitor, decreased TCR-stimulated IL-2 mRNA levels. Gαs siRNA, but not GαsDN3, decreased TCR-stimulated cAMP synthesis. Potentiation of IL-2 mRNA levels by ZM-241385 required at least two days of TCR stimulation, and addition of ddA after three days of TCR stimulation enhanced IL-2 mRNA levels.

Conclusions: GsPCRs play an inhibitory role in the regulation of TCR-stimulated IL-2 mRNA levels whereas Gαs and cAMP can play a stimulatory one. Additionally, TCR-dependent activation of Gαs does not appear to involve GsPCRs. These results suggest that the context of Gαs/cAMP activation and the stage of T cell activation and differentiation determine the effect on TCR-stimulated IL-2 mRNA levels.

Citing Articles

CD73, a significant protein in liver diseases.

Shi H, Dai H, Sun Q, Wang S, Chen Y Front Med (Lausanne). 2023; 10:1147782.

PMID: 37122331 PMC: 10130655. DOI: 10.3389/fmed.2023.1147782.

Soluble adenylyl cyclase contributes to imiquimod-mediated inflammation and is a potential therapeutic target in psoriasis.

You J, Reilly M, Eljalby M, Bareja R, Yusupova M, Vyas N Exp Dermatol. 2023; 32(7):1051-1062.

PMID: 37039485 PMC: 10523866. DOI: 10.1111/exd.14811.

Purinergic signalling in liver diseases: Pathological functions and therapeutic opportunities.

Wang P, Jia J, Zhang D JHEP Rep. 2020; 2(6):100165.

PMID: 33103092 PMC: 7575885. DOI: 10.1016/j.jhepr.2020.100165.

The GS Protein-coupled A2a Adenosine Receptor Controls T Cell Help in the Germinal Center.

Abbott R, Silva M, Labuda J, Thayer M, Cain D, Philbrook P J Biol Chem. 2016; 292(4):1211-1217.

PMID: 27974461 PMC: 5270467. DOI: 10.1074/jbc.C116.764043.

References

Boomer J, Green J . An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol. 2010; 2(8):a002436. PMC: 2908766. DOI: 10.1101/cshperspect.a002436. View

Koh W, Yang K, Kaminski N . Cyclic AMP is an essential factor in immune responses. Biochem Biophys Res Commun. 1995; 206(2):703-9. DOI: 10.1006/bbrc.1995.1099. View

Vang T, Torgersen K, Sundvold V, Saxena M, Levy F, Skalhegg B . Activation of the COOH-terminal Src kinase (Csk) by cAMP-dependent protein kinase inhibits signaling through the T cell receptor. J Exp Med. 2001; 193(4):497-507. PMC: 2195911. DOI: 10.1084/jem.193.4.497. View

Lee E, Taussig R, GILMAN A . The G226A mutant of Gs alpha highlights the requirement for dissociation of G protein subunits. J Biol Chem. 1992; 267(2):1212-8. View

Grishina G, Berlot C . Identification of common and distinct residues involved in the interaction of alphai2 and alphas with adenylyl cyclase. J Biol Chem. 1997; 272(33):20619-26. DOI: 10.1074/jbc.272.33.20619. View

Abrahamsen H, Baillie G, Ngai J, Vang T, Nika K, Ruppelt A . TCR- and CD28-mediated recruitment of phosphodiesterase 4 to lipid rafts potentiates TCR signaling. J Immunol. 2004; 173(8):4847-58. DOI: 10.4049/jimmunol.173.8.4847. View

Pastan I, Johnson G, Anderson W . Role of cyclic nucleotides in growth control. Annu Rev Biochem. 1975; 44:491-522. DOI: 10.1146/annurev.bi.44.070175.002423. View

Otani S, Matsui-Yuasa I, Morisawa S . Biphasic effects of dibutyryl cyclic adenosine 3',5'-monophosphate on synergistic stimulation of DNA synthesis by diacylglycerol, and the ionophore A23187 in guinea pig lymphocytes. Life Sci. 1987; 40(25):2409-14. DOI: 10.1016/0024-3205(87)90755-7. View

Bruzzone A, Sauliere A, Finana F, Senard J, Luthy I, Gales C . Dosage-dependent regulation of cell proliferation and adhesion through dual β2-adrenergic receptor/cAMP signals. FASEB J. 2013; 28(3):1342-54. DOI: 10.1096/fj.13-239285. View

10.

Poucher S, Keddie J, Singh P, Stoggall S, Caulkett P, Jones G . The in vitro pharmacology of ZM 241385, a potent, non-xanthine A2a selective adenosine receptor antagonist. Br J Pharmacol. 1995; 115(6):1096-102. PMC: 1909020. DOI: 10.1111/j.1476-5381.1995.tb15923.x. View

11.

Junger W . Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011; 11(3):201-12. PMC: 4209705. DOI: 10.1038/nri2938. View

12.

Johannessen M, Delghandi M, Moens U . What turns CREB on?. Cell Signal. 2004; 16(11):1211-27. DOI: 10.1016/j.cellsig.2004.05.001. View

13.

Bodor J, Spetz A, Strominger J, Habener J . cAMP inducibility of transcriptional repressor ICER in developing and mature human T lymphocytes. Proc Natl Acad Sci U S A. 1996; 93(8):3536-41. PMC: 39645. DOI: 10.1073/pnas.93.8.3536. View

14.

Ohta A, Ohta A, Madasu M, Kini R, Subramanian M, Goel N . A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol. 2009; 183(9):5487-93. DOI: 10.4049/jimmunol.0901247. View

15.

Harada K, Miyake H, Kurahashi T, Fujisawa M . Long-term complete response to very-low-dose interleukin-2 therapy in patients with metastatic renal cell carcinoma: report of two cases. Clin Exp Nephrol. 2011; 15(6):966-9. DOI: 10.1007/s10157-011-0518-x. View

16.

Abraham R, Weiss A . Jurkat T cells and development of the T-cell receptor signalling paradigm. Nat Rev Immunol. 2004; 4(4):301-8. DOI: 10.1038/nri1330. View

17.

Schulze-Koops H, Lipsky P, Kavanaugh A, Davis L . Elevated Th1- or Th0-like cytokine mRNA in peripheral circulation of patients with rheumatoid arthritis. Modulation by treatment with anti-ICAM-1 correlates with clinical benefit. J Immunol. 1995; 155(10):5029-37. View

18.

Goodwin J, Bromberg S, Messner R . Studies on the cyclic AMP response to prostaglandin in human lymphocytes. Cell Immunol. 1981; 60(2):298-307. DOI: 10.1016/0008-8749(81)90271-9. View

19.

Csoka B, Himer L, Selmeczy Z, Vizi E, Pacher P, Ledent C . Adenosine A2A receptor activation inhibits T helper 1 and T helper 2 cell development and effector function. FASEB J. 2008; 22(10):3491-9. PMC: 2537430. DOI: 10.1096/fj.08-107458. View

20.

Natochin M, Campbell T, Barren B, Miller L, Hameed S, Artemyev N . Characterization of the G alpha(s) regulator cysteine string protein. J Biol Chem. 2005; 280(34):30236-41. DOI: 10.1074/jbc.M500722200. View